INDIUM IN 111 OXYQUINOLINE Drug Patent Profile

Which patents cover Indium In 111 Oxyquinoline, and when can generic versions of Indium In 111 Oxyquinoline launch?

Indium In 111 Oxyquinoline is a drug marketed by Bwxt Itg and Ge Healthcare and is included in two NDAs.

The generic ingredient in INDIUM IN 111 OXYQUINOLINE is indium in-111 oxyquinoline. There are twenty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the indium in-111 oxyquinoline profile page.

Summary for INDIUM IN 111 OXYQUINOLINE

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	7
Patent Applications:	21
What excipients (inactive ingredients) are in INDIUM IN 111 OXYQUINOLINE?	INDIUM IN 111 OXYQUINOLINE excipients list
DailyMed Link:	INDIUM IN 111 OXYQUINOLINE at DailyMed

US Patents and Regulatory Information for INDIUM IN 111 OXYQUINOLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bwxt Itg	INDIUM IN 111 OXYQUINOLINE	indium in-111 oxyquinoline	INJECTABLE;INJECTION	202586-001	Jul 25, 2018	AP	RX	No	No
Ge Healthcare	INDIUM IN 111 OXYQUINOLINE	indium in-111 oxyquinoline	INJECTABLE;INJECTION	019044-001	Dec 24, 1985	AP	RX	Yes	Yes

Expired US Patents for INDIUM IN 111 OXYQUINOLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	INDIUM IN 111 OXYQUINOLINE	indium in-111 oxyquinoline	INJECTABLE;INJECTION	019044-001	Dec 24, 1985	4,335,095

International Patents for INDIUM IN 111 OXYQUINOLINE

See the table below for patents covering INDIUM IN 111 OXYQUINOLINE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S55129229	INDIUMM1111OXINE COMPLEX COMPOSITION
Germany	3062496
Japan	S5914452
European Patent Office	0017355	INDIUM-111 OXINE COMPLEX COMPOSITION

INDIUM IN 111 OXYQUINOLINE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Indium In 111 Oxyquinoline

Introduction

Indium In 111 oxyquinoline is a diagnostic radiopharmaceutical used for radiolabeling autologous leukocytes, primarily in the detection of inflammatory processes and infections. Understanding the market dynamics and financial trajectory of this drug is crucial for healthcare organizations, manufacturers, and investors.

Market Overview

The market for radiopharmaceuticals, including Indium In 111 oxyquinoline, is influenced by several key factors:

Demand and Usage

Indium In 111 oxyquinoline is used as an adjunct in the detection of inflammatory processes, such as abscesses or other infections, by labeling leukocytes that migrate to these sites. The demand for this drug is driven by the need for accurate diagnostic tools in nuclear medicine[4].

Supply Chain and Manufacturing

The production of Indium In 111 oxyquinoline involves complex manufacturing processes, including the synthesis of the oxyquinoline complex and the handling of radioactive materials. This complexity can lead to supply chain vulnerabilities and cost increases, particularly with the need to transition to non-highly enriched uranium (HEU) sources[3].

Pricing and Cost Dynamics

The cost of Indium In 111 oxyquinoline and other radiopharmaceuticals has seen significant increases over the years. Factors contributing to these price hikes include the high cost of manufacturing the non-radioactive portion (ligand) of the radiopharmaceutical, consolidation within the industry leading to sole-source producers, and the need for full cost recovery and outage reserve capacity to maintain supply[3].

Financial Trajectory

Cost Implications for Healthcare Organizations

Healthcare organizations face substantial financial challenges due to the rising costs of radiopharmaceuticals. These costs can become a dominant part of the total procedure cost, potentially turning bundled reimbursement models into loss leaders. This situation may force healthcare organizations to either absorb the increased costs or opt for less efficacious diagnostic tests, which could compromise patient outcomes[3].

Reimbursement Models

The financial sustainability of using Indium In 111 oxyquinoline and other radiopharmaceuticals depends heavily on reimbursement models. There is a need for timely and appropriate reimbursement strategies to ensure that healthcare organizations can continue to provide these diagnostic tools without incurring significant financial burdens[3].

Industry Consolidation and Sole-Source Producers

The radiopharmaceutical market has seen significant consolidation, leading to the emergence of sole-source producers. This consolidation can result in higher prices and reduced competition, further complicating the financial landscape for healthcare providers[3].

Regulatory and Economic Factors

Regulatory Environment

Regulatory requirements and changes in the regulatory environment can significantly impact the market dynamics of Indium In 111 oxyquinoline. For instance, the transition to non-HEU sources and the implementation of full cost recovery mechanisms can increase production costs and, subsequently, the final cost to healthcare organizations[3].

Economic Impact on Patients and Healthcare Systems

The economic impact of rising radiopharmaceutical costs extends beyond healthcare organizations to patients and the broader healthcare system. Higher costs can lead to reduced access to diagnostic imaging, particularly for patients who cannot afford the increased expenses. This can result in delayed diagnoses and potentially worse health outcomes[3].

Market Trends and Future Outlook

Technological Advancements

Advancements in nuclear medicine and diagnostic imaging technologies may influence the demand for Indium In 111 oxyquinoline. Newer diagnostic agents and imaging modalities could potentially replace or complement existing radiopharmaceuticals, affecting market dynamics[4].

Theranostics and Personalized Medicine

The growing field of theranostics, which combines diagnostic and therapeutic treatments tailored to individual patients, may also impact the market for Indium In 111 oxyquinoline. As theranostics becomes more prevalent, the demand for specific radiopharmaceuticals could shift, influencing their financial trajectory[3].

Key Takeaways

• Demand and Supply: The demand for Indium In 111 oxyquinoline is driven by the need for accurate diagnostic tools in nuclear medicine, while supply chain complexities and manufacturing costs contribute to price increases.
• Financial Burden: Rising costs of radiopharmaceuticals pose significant financial challenges for healthcare organizations, potentially affecting patient outcomes.
• Regulatory Environment: Changes in regulatory requirements, such as the transition to non-HEU sources, can increase production costs.
• Market Trends: Technological advancements and the growth of theranostics may influence the future demand and financial trajectory of Indium In 111 oxyquinoline.

FAQs

What is Indium In 111 oxyquinoline used for?

Indium In 111 oxyquinoline is a diagnostic radiopharmaceutical used for radiolabeling autologous leukocytes to detect inflammatory processes and infections[4].

How does Indium In 111 oxyquinoline work?

The drug forms a lipid-soluble complex with oxyquinoline, allowing it to penetrate cell membranes. Once inside, indium detaches from oxyquinoline and attaches to cytoplasmic components, enabling the detection of leukocyte migration to inflammatory sites[2].

What are the key factors influencing the cost of Indium In 111 oxyquinoline?

The cost is influenced by manufacturing complexities, industry consolidation, the need for full cost recovery, and the transition to non-HEU sources[3].

How do reimbursement models affect the use of Indium In 111 oxyquinoline?

Appropriate reimbursement models are crucial to ensure that healthcare organizations can afford the increasing costs of radiopharmaceuticals without compromising patient care[3].

What are the potential future trends in the market for Indium In 111 oxyquinoline?

Future trends may include the impact of technological advancements in nuclear medicine and the growth of theranostics, which could shift demand and influence the financial trajectory of the drug[3].

Sources

1. DailyMed: Indium In-111 oxyquinoline solution - DailyMed
2. FDA: INDIUM In 111 OXYQUINOLINE SOLUTION - accessdata.fda.gov
3. RPOF Indy: Can the SPECT nuclear imaging modality be sustained? - rpofindy.com
4. DrugBank: Indium In-111 oxyquinoline: Uses, Interactions, Mechanism of Action - go.drugbank.com
5. DailyMed: Indium 111 Oxyquinolone (In-111 Oxine) - DailyMed